MK-5172 sodium saltHCV NS3/4a protease inhibitor CAS# 1425038-27-2 |
- MK-5172 potassium salt
Catalog No.:BCC1764
CAS No.:1206524-86-8
- MK-5172 hydrate
Catalog No.:BCC1763
CAS No.:1350462-55-3
- MK-5172
Catalog No.:BCC1762
CAS No.:1350514-68-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1425038-27-2 | SDF | Download SDF |
PubChem ID | 72187677 | Appearance | Powder |
Formula | C38H50N6NaO9S+ | M.Wt | 789.89 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | Grazoprevir sodium salt | ||
Solubility | Soluble in DMSO | ||
SMILES | CC(C)(C)C1C(=O)N2CC(CC2C(=O)NC3(CC3C=C)C(=O)[N-]S(=O)(=O)C4CC4)OC5=NC6=C(C=CC(=C6)OC)N=C5CCCCCC7CC7OC(=O)N1.[Na+] | ||
Standard InChIKey | HWKZBIVJZNPHGU-CIAYNJNFSA-M | ||
Standard InChI | InChI=1S/C38H50N6O9S.Na/c1-6-22-19-38(22,35(47)43-54(49,50)25-13-14-25)42-32(45)29-18-24-20-44(29)34(46)31(37(2,3)4)41-36(48)53-30-16-21(30)10-8-7-9-11-27-33(52-24)40-28-17-23(51-5)12-15-26(28)39-27;/h6,12,15,17,21-22,24-25,29-31H,1,7-11,13-14,16,18-20H2,2-5H3,(H3,41,42,43,45,47,48);/q;+1/p-1/t21-,22-,24-,29+,30-,31-,38-;/m1./s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.
IC50 Value: 7.4 nM and 7 nM for genotype 1b and 1a respectively, in replicon system [1]
Target: HCV NS3/4a protease
in vitro: In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a [2].
in vivo: In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose [1].
Clinical trial: Evaluation of Hepatic Pharmacokinetics for MK-5172 in Participants With Chronic Hepatitis C . Phase1 References: |
MK-5172 sodium salt Dilution Calculator
MK-5172 sodium salt Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.266 mL | 6.33 mL | 12.66 mL | 25.32 mL | 31.65 mL |
5 mM | 0.2532 mL | 1.266 mL | 2.532 mL | 5.064 mL | 6.33 mL |
10 mM | 0.1266 mL | 0.633 mL | 1.266 mL | 2.532 mL | 3.165 mL |
50 mM | 0.0253 mL | 0.1266 mL | 0.2532 mL | 0.5064 mL | 0.633 mL |
100 mM | 0.0127 mL | 0.0633 mL | 0.1266 mL | 0.2532 mL | 0.3165 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
IC50 Value: 7.4nM and 7nM for genotype1b and 1a respectively, in replicon system [1] MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development. in vitro: In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a [2]. in vivo: In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose [1]. Clinical trial: Evaluation of Hepatic Pharmacokinetics for MK-5172 in Participants With Chronic Hepatitis C . Phase1
- 19-Nortestosterone acetate
Catalog No.:BCC8445
CAS No.:1425-10-1
- Glyasperin A
Catalog No.:BCN6228
CAS No.:142474-52-0
- 3-O-beta-D-apiofuranosyl(1-2)-beta-D-glucopyranosyl rhamnocitrin 4-O-beta-D-glucopyranoside
Catalog No.:BCN8141
CAS No.:142473-99-2
- Amthamine dihydrobromide
Catalog No.:BCC6744
CAS No.:142457-00-9
- Lobetyolinin
Catalog No.:BCN3322
CAS No.:142451-48-7
- Myricetin 3-O-beta-D-xylopyranosyl(1-2)-beta-D-glucopyranoside
Catalog No.:BCN8140
CAS No.:142449-93-2
- NHS-SS-Biotin
Catalog No.:BCC3581
CAS No.:142439-92-7
- Crovatin
Catalog No.:BCN2517
CAS No.:142409-09-4
- Mesterolone
Catalog No.:BCC9023
CAS No.:1424-00-6
- Didemethylpseudoaspidin AA
Catalog No.:BCN3777
CAS No.:142382-28-3
- 7alpha-Hydroxy-4,11-cadinadiene-3,8-dione
Catalog No.:BCN7057
CAS No.:1423809-64-6
- FR 139317
Catalog No.:BCC5733
CAS No.:142375-60-8
- L-690,488
Catalog No.:BCC5667
CAS No.:142523-14-6
- L-690,330
Catalog No.:BCC5666
CAS No.:142523-38-4
- 1,2,3,4,7-Pentamethoxy-9H-xanthen-9-one
Catalog No.:BCN1570
CAS No.:14254-96-7
- Cimidahurinine
Catalog No.:BCN6229
CAS No.:142542-89-0
- Sageone
Catalog No.:BCN3144
CAS No.:142546-15-4
- A 484954
Catalog No.:BCC6203
CAS No.:142557-61-7
- Glyasperin D
Catalog No.:BCN6836
CAS No.:142561-10-2
- Calanolide E
Catalog No.:BCN6230
CAS No.:142566-61-8
- Asperuloside
Catalog No.:BCN6231
CAS No.:14259-45-1
- Narirutin
Catalog No.:BCN6300
CAS No.:14259-46-2
- Didymin
Catalog No.:BCN3327
CAS No.:14259-47-3
- Deacetylasperulosidic acid
Catalog No.:BCN3323
CAS No.:14259-55-3